Ngā hua rapu - Kee‐Young Shin
- E whakaatu ana i te 1 - 2 hua o te 2
-
1
Epigenetic therapy sensitizes anti–PD-1 refractory head and neck cancers to immunotherapy rechallenge mā Tingting Qin, Austin K. Mattox, Jean S. Campbell, Jong Chul Park, Kee-Young Shin, Shiting Li, Peter M. Sadow, William C. Faquin, Goran Micevic, Andrew J. Daniels, Robert I. Haddad, Christopher Garris, Mikaël J. Pittet, Thorsten R. Mempel, Anne O’Neill, Maureen A. Sartor, Sara I. Pai
I whakaputaina 2025Artigo -
2
Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck mā Glenn J. Hanna, Anne O’Neill, Kee‐Young Shin, Kristine Wong, Vickie Y. Jo, Charles T. Quinn, Jennifer M. Cutler, Michelle Flynn, Patrick H. Lizotte, Donald J. Annino, Laura A. Goguen, Jason Kass, Eleni M. Rettig, Rosh K.V. Sethi, Jochen H. Lorch, Jonathan D. Schoenfeld, Danielle N. Margalit, Roy B. Tishler, Peter C. Everett, Anupam M. Desai, Megan E. Cavanaugh, Cloud P. Paweletz, Ann Marie Egloff, Ravindra Uppaluri, Robert I. Haddad
I whakaputaina 2021Artigo
Ngā utauta rapu:
Ngā marau whai pānga
Head and neck
Immunotherapy
Internal medicine
Medicine
Oncology
Surgery
Adjuvant
Astrobiology
Basal cell
Biochemistry
Biology
Cancer
Cancer research
Chemotherapy
DNA methylation
Epigenetic therapy
Epigenetics
Gene
Gene expression
Head and neck cancer
Head and neck squamous-cell carcinoma
Immune system
Immunology
Nivolumab
Radiation therapy
Refractory (planetary science)